| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Author index
|
|
|
|
200 |
S1 |
p. S82-S88
|
artikel
|
| 2 |
Copyright
|
|
|
|
200 |
S1 |
p. iv
|
artikel
|
| 3 |
Editorial Board
|
|
|
|
200 |
S1 |
p. ii
|
artikel
|
| 4 |
OC-13 A clinical-genetic risk score to predict cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts
|
Muñoz, A.
|
|
|
200 |
S1 |
p. S12-S13
|
artikel
|
| 5 |
OC-16 Apixaban as treatment for cancer-associated venous thrombosis: the CAP study
|
Hannevik, T.L.
|
|
|
200 |
S1 |
p. S15-S16
|
artikel
|
| 6 |
OC-08 Biomarkers of venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis (HISPALIS study)
|
Otero Candelera, R.
|
|
|
200 |
S1 |
p. S8
|
artikel
|
| 7 |
OC-12 D-dimer levels significantly decline in ambulatory cancer patients receiving rivaroxaban compared to placebo: biomarker analysis of the CASSINI trial
|
Vadhan-Raj, S.
|
|
|
200 |
S1 |
p. S12
|
artikel
|
| 8 |
OC-07 Differences in thromboprophylaxis between hospitalized patients with solid or hematological malignancies
|
Figueroa, R.
|
|
|
200 |
S1 |
p. S7
|
artikel
|
| 9 |
OC-03 Heparin treatment in COVID-19 patients is associated with reduced in-hospital mortality: findings from an observational multicenter study in Italy and a meta-analysis of 11 studies
|
Costanzo, S.
|
|
|
200 |
S1 |
p. S2-S3
|
artikel
|
| 10 |
OC-04 Incidence, predictors and clinical outcomes of venous thromboembolism in patients with newly diagnosed pancreatic ductal adenocarcinoma: results of the prospective BACAP-VTE study
|
Frere, C.
|
|
|
200 |
S1 |
p. S4
|
artikel
|
| 11 |
OC-02 Khorana risk score at diagnosis of SARS-CoV-2 infection as a predicting tool for venous thromboembolic disease development, and overall mortality, in cancer patients
|
López Jiménez, C.
|
|
|
200 |
S1 |
p. S1-S2
|
artikel
|
| 12 |
OC-11 Plasminogen activator inhibitor 1 enhances venous thrombosis in pancreatic cancer
|
Hisada, Y.
|
|
|
200 |
S1 |
p. S10-S11
|
artikel
|
| 13 |
OC-09 Proteomic profiling in cancer-associated VTE
|
Panova-Noeva, M.
|
|
|
200 |
S1 |
p. S8-S9
|
artikel
|
| 14 |
OC-14 Risk factors for recurrence in patients with cancer-associated venous thromboembolism: results from the Hokusai-VTE cancer study
|
Bosch, F.T.M.
|
|
|
200 |
S1 |
p. S14-S15
|
artikel
|
| 15 |
OC-15 Risk factors of recurrence in cancer-associated venous thromboembolism after discontinuation of anticoagulant therapy: a RIETE-based prospective study
|
Lapébie, F.X.
|
|
|
200 |
S1 |
p. S15
|
artikel
|
| 16 |
OC-05 Risk of venous thromboembolism in cancer patients: a cohort study
|
Mulder, F.I.
|
|
|
200 |
S1 |
p. S5
|
artikel
|
| 17 |
OC-17 Rivaroxaban vesus Dalteparin for the Treatment of Cancer- Associated Venous Thromboembolism: the CASTA DIVA Trial
|
Meyer, G.
|
|
|
200 |
S1 |
p. S16
|
artikel
|
| 18 |
OC-06 The molecular mechanisms of ponatinib-induced thrombosis
|
Schmaier, A.H.
|
|
|
200 |
S1 |
p. S6
|
artikel
|
| 19 |
OC-10 Thrombin tips the scales towards effective immune checkpoint blockade in cancer
|
Cantrell, R.
|
|
|
200 |
S1 |
p. S10
|
artikel
|
| 20 |
OC-01 Venous thromboembolic events during the first and second waves of Covid-19 in breast cancer patients treated in an outpatient day hospital
|
Illarramendi, J.
|
|
|
200 |
S1 |
p. S1
|
artikel
|
| 21 |
PO-34 A case of normal range D-dimer levels in a patient with deep vein thrombosis and active cancer
|
Muster, V.
|
|
|
200 |
S1 |
p. S34-S35
|
artikel
|
| 22 |
PO-95 Adverse events of rivaroxaban usage in younger versus older cancer patients
|
Escalante, C.P.
|
|
|
200 |
S1 |
p. S71-S72
|
artikel
|
| 23 |
PO-35 Analysis of coagulation parameters in patients with COVID-19, data from Regional Center Shtip
|
Shorova, M.
|
|
|
200 |
S1 |
p. S35
|
artikel
|
| 24 |
PO-93 Analysis of the safety profiles of anticoagulants using the EMA pharmacovigilance database
|
Elalamy, I.
|
|
|
200 |
S1 |
p. S70
|
artikel
|
| 25 |
PO-68 Analysis of thrombosis and neoplasia pre and postdiagnosis of essential thrombocytemia : implication in survival
|
Cuevas, M.V.
|
|
|
200 |
S1 |
p. S54
|
artikel
|
| 26 |
PO-06 A novel approach to venous thromboembolism thromboprophylaxis in multiple myeloma: a single-centre approach
|
Sayar, Z.
|
|
|
200 |
S1 |
p. S19-S20
|
artikel
|
| 27 |
PO-108 Antiangiogenic effects of acetylsalicylic acid in patients with polycythemia vera
|
Shabalina, A.
|
|
|
200 |
S1 |
p. S78
|
artikel
|
| 28 |
PO-59 Anticoagulant therapy as a potential intervention to prevent relapse in patients with advanced ovarian cancer
|
Vorobyev, A.V.
|
|
|
200 |
S1 |
p. S49
|
artikel
|
| 29 |
PO-70 Anti-tumour miR-7-5p as a novel regulator of TFPI in liver cancer
|
Skogstrøm, K.B.
|
|
|
200 |
S1 |
p. S56
|
artikel
|
| 30 |
PO-83 Assessment model for thrombotic risk in a prospective cohort of newly diagnosed metastatic cancer outpatient candidates for chemotherapy
|
Verzeroli, C.
|
|
|
200 |
S1 |
p. S62
|
artikel
|
| 31 |
PO-43 A unique approach to anticoagulation in a morbidly obese patient with endometrial cancer and venous thromboembolism
|
Tso, M.T.
|
|
|
200 |
S1 |
p. S39
|
artikel
|
| 32 |
PO-102 Bleeding management challenges in rare cancer-associated thrombosis: a case report of inferior vena cava thrombus in a patient with testicular germ cell tumour
|
Gramaça, J.
|
|
|
200 |
S1 |
p. S74-S75
|
artikel
|
| 33 |
PO-111 Blood group B is a potent risk factor for venous thromboembolism in glioblastoma multiforme
|
Heenkenda, K.M.
|
|
|
200 |
S1 |
p. S80
|
artikel
|
| 34 |
PO-08 Cancer outpatients under thromboprophylaxis: an analysis of choices and events
|
Liz Pimenta, J.
|
|
|
200 |
S1 |
p. S21-S22
|
artikel
|
| 35 |
PO-86 Can we improve the prediction of the rate of complications following pulmonary embolism diagnosis in cancer patients? Prospective validation of the epiphany INDEX: the PERSEO study
|
Sánchez Cánovas, M.
|
|
|
200 |
S1 |
p. S63-S65
|
artikel
|
| 36 |
PO-31 Changes in ADAMTS13 and vWF activity as a potential predictor of thrombotic complications in women with ovarian cancer undergoing chemotherapy
|
Vorobyev, A.V.
|
|
|
200 |
S1 |
p. S33
|
artikel
|
| 37 |
PO-57 Characteristics of venous thromboembolism following COVID-19 in Croatia
|
Barišić, B.
|
|
|
200 |
S1 |
p. S47
|
artikel
|
| 38 |
PO-90 Characterization of thrombosis risk in patients with cancer: preliminary results
|
Trujillo-Santos, J.
|
|
|
200 |
S1 |
p. S67
|
artikel
|
| 39 |
PO-28 Circulating markers of neutrophil activation and nets, but not of coagulation and fibrinolysis, predict mortality in patients with terminal cancer
|
Rosell, A.
|
|
|
200 |
S1 |
p. S32
|
artikel
|
| 40 |
PO-49 CNS thrombosis as initial symptom of ALK+ALCL in a child
|
Karametou, M.
|
|
|
200 |
S1 |
p. S42-S43
|
artikel
|
| 41 |
PO-73 Coagulation-cancer crosstalk: defining the role of von Willebrand factor in breast cancer progression
|
Patmore, S.
|
|
|
200 |
S1 |
p. S57
|
artikel
|
| 42 |
PO-72 Coagulome analyses reveal possible onco-immunological role of coagulation factor V in breast cancer
|
Tinholt, M.
|
|
|
200 |
S1 |
p. S57
|
artikel
|
| 43 |
PO-87 Comparison of different clinical risk assessment models (RAMs) in ambulatory cancer patients receiving chemotherapy from the Oncothromb-02 study
|
Muñoz Martín, A.
|
|
|
200 |
S1 |
p. S65
|
artikel
|
| 44 |
PO-07 Comparison of primary thromboprophylaxis agents (PTA) efficacy in multiple myeloma (MM) treated with immunomodulators (IMID): a network meta-analysis
|
Haddad, P.
|
|
|
200 |
S1 |
p. S20-S21
|
artikel
|
| 45 |
PO-78 Comparison of the inhibitory effect of angiostatin K1-4.5 and new plasminogen fragment K1-5 on generation of plasmin from plasminogen and angiogenesis
|
Aisina, R.B.
|
|
|
200 |
S1 |
p. S59
|
artikel
|
| 46 |
PO-109 D-dimer, P-selectin and microparticles as biomarkers of occult cancer in unprovoked venous thromboembolism (VTE) patients
|
Marín Romero, S.
|
|
|
200 |
S1 |
p. S78-S79
|
artikel
|
| 47 |
PO-40 Educational and financial impact of a recommendation on cancer-associated thrombosis (CAT) management: experience of a Brazilian oncological Public Hospital for adults
|
Rothschild, C.
|
|
|
200 |
S1 |
p. S38
|
artikel
|
| 48 |
PO-106 Effect of single dose prophylactic bemiparin on the levels of citrullinated histone in cancer hospitalized patient
|
Figueroa, R.
|
|
|
200 |
S1 |
p. S77-S78
|
artikel
|
| 49 |
PO-63 Empowering cancer patients for non-pharmacological primary prevention and early recognition of cancer-associated thrombosis (CAT): the EMPATIC-CP survey
|
Merino, M.
|
|
|
200 |
S1 |
p. S51-S52
|
artikel
|
| 50 |
PO-10 Epidemiology of venous thromboembolism after development of second cancer
|
Gade, I.L.
|
|
|
200 |
S1 |
p. S23-S24
|
artikel
|
| 51 |
PO-92 Evaluation of gemcitabine and platinum agents for the prediction of venous thromboembolism in patients with cancer: results from the Vienna Cancer and thrombosis Study
|
Moik, A.
|
|
|
200 |
S1 |
p. S68-S69
|
artikel
|
| 52 |
PO-26 Fibrinogen levels and risk of colorectal cancer in a case–cohort study from the Italian general adult population: results from the Moli-sani study
|
Costanzo, S.
|
|
|
200 |
S1 |
p. S31
|
artikel
|
| 53 |
PO-85 Finding a risk assessment model for thromboembolic events in hospitalized cancer patients: the INDICATE study
|
Nichetti, F.
|
|
|
200 |
S1 |
p. S63
|
artikel
|
| 54 |
PO-112 Forthcoming study of a novel assay for the stratification of cancer patients' risk of thromboembolism
|
Tzoran, I.
|
|
|
200 |
S1 |
p. S80-S81
|
artikel
|
| 55 |
PO-44 Health care resource utilization and costs associated with venous thromboembolism recurrence in cancer patients: SELECT-D trial
|
Maredza, M.
|
|
|
200 |
S1 |
p. S39-S40
|
artikel
|
| 56 |
PO-33 Hemostatic activation and fibrinolysis with prostate cancer before and after hormonal therapy
|
Nauseef, J.
|
|
|
200 |
S1 |
p. S34
|
artikel
|
| 57 |
PO-37 How are patients with active cancer and venous thromboembolism (VTE) treated in Germany? Answers from GECAT (German Evaluation of Cancer Associated Thrombosis)
|
Sinn, M.
|
|
|
200 |
S1 |
p. S36-S37
|
artikel
|
| 58 |
PO-23 Hypercoagulabilty in upper gastrointestinal cancer patients: a longitudinal study
|
Larsen, A.C.
|
|
|
200 |
S1 |
p. S30
|
artikel
|
| 59 |
PO-110 Identification of novel biomarkers to aid in the detection of occult cancer in high-risk patient populations: the BIT and MEDECA studies
|
Thålin, C.
|
|
|
200 |
S1 |
p. S79-S80
|
artikel
|
| 60 |
PO-52 Immunophenotypic analysis of haematological malignancies in a Pakistani population: a step towards formulation of hospital cancer registry
|
Memon, A.M.
|
|
|
200 |
S1 |
p. S44
|
artikel
|
| 61 |
PO-82 Impede VTE vs saved scores to predict the risk of venous thromboembolism in newly diagnosed multiple myeloma with immunomodulatory drugs: how to choose?
|
Teste, A.
|
|
|
200 |
S1 |
p. S61-S62
|
artikel
|
| 62 |
PO-91 Implementing an automated electronic VTE assessment tool for ambulatory oncology patients: a Canadian community cancer centre experience
|
Rotz, L.J.
|
|
|
200 |
S1 |
p. S68
|
artikel
|
| 63 |
PO-84 Incidence of venous thromboembolism and Khorana score in patients with sarcoma: a retrospective study in a single institution
|
Figaredo Berjano, C.
|
|
|
200 |
S1 |
p. S62-S63
|
artikel
|
| 64 |
PO-21 Incidence of venous thromboembolism events in outpatients with cancer and COVID-19.
|
Gutiérrez Ortiz de la Tabla, A.
|
|
|
200 |
S1 |
p. S27-S28
|
artikel
|
| 65 |
PO-20 Incidence of venous thromboembolism in men with prostate cancer and men without prostate cancer: a nationwide population-based cohort study in Sweden
|
Farahmand, B.
|
|
|
200 |
S1 |
p. S27
|
artikel
|
| 66 |
PO-46 Incident cardiovascular events after diagnosis of breast cancer: a cohort study in 682 patients
|
Mery, B.
|
|
|
200 |
S1 |
p. S41-S42
|
artikel
|
| 67 |
PO-30 Inherited deficiency of antithrombin, protein C or protein S is associated with an increased risk of cancer at a younger age
|
Tormene, D.
|
|
|
200 |
S1 |
p. S32-S33
|
artikel
|
| 68 |
PO-19 Initiation of low-dose aspirin and risk of colorectal neoplasms: a population-based matched cohort study in Denmark
|
Schønfeldt Troelsen, E.
|
|
|
200 |
S1 |
p. S26
|
artikel
|
| 69 |
PO-32 Integral laboratory hemostasis tests in diagnosis of hypercoagulation and assessment of thrombosis risk in patients with brain glioma
|
Vasilenko, I.A.
|
|
|
200 |
S1 |
p. S33-S34
|
artikel
|
| 70 |
PO-94 Intracranial hemorrhage with direct oral anticoagulants in patients with primary or secondary brain tumors
|
Leader, A.
|
|
|
200 |
S1 |
p. S70-S71
|
artikel
|
| 71 |
PO-03 Is extended thromboprophylaxis required for all gynaecological cancer patients post-surgery?
|
Abu Saadeh, F.
|
|
|
200 |
S1 |
p. S18
|
artikel
|
| 72 |
PO-45 Long-term anticoagulation for the treatment and secondary prophylaxis of venous thromboembolism among men with prostate cancer in Sweden: risk of recurrent venous thromboembolism and major bleeding
|
Brobert, G.
|
|
|
200 |
S1 |
p. S40
|
artikel
|
| 73 |
PO-24 Lung cancer: the clinical profile of D-dimers
|
Kokkotou, E.
|
|
|
200 |
S1 |
p. S30
|
artikel
|
| 74 |
PO-38 Management of cancer associated thrombosis in Denmark: findings from a nationwide survey
|
Højen, A.A.
|
|
|
200 |
S1 |
p. S37
|
artikel
|
| 75 |
PO-101 Management of direct oral anticoagulant (DOAC)-related bleeding with andexanet alpha or idarucizumab versus prothrombin complex concentrate (PCC) in patients with cancer: the MD Anderson experience
|
Ross, J.A.
|
|
|
200 |
S1 |
p. S74
|
artikel
|
| 76 |
PO-17 Mesothelioma: a retrospective study of thromboembolism events
|
Dimakakos, E.
|
|
|
200 |
S1 |
p. S26
|
artikel
|
| 77 |
PO-104 Microparticles signature in pancreatic cancer: the BACAP project
|
Mege, D.
|
|
|
200 |
S1 |
p. S76
|
artikel
|
| 78 |
PO-99 Non-traumatic subdural hematoma and occult cancer: a Danish nationwide cohort study
|
Okholm, S.H.
|
|
|
200 |
S1 |
p. S73
|
artikel
|
| 79 |
PO-55 Outcomes and a predictive model for survival in postoperative endometrial cancer patients with venous thromboembolism
|
Easaw, J.
|
|
|
200 |
S1 |
p. S45
|
artikel
|
| 80 |
PO-97 Overall survival with warfarin versus low-molecular-weight heparin in cancer-associated thrombosis
|
Patell, R.
|
|
|
200 |
S1 |
p. S72-S73
|
artikel
|
| 81 |
PO-41 Paraneoplastic deep vein thrombosis in pre-existing full-dose anticoagulation with dabigatran: a case report
|
Guetl, K.
|
|
|
200 |
S1 |
p. S38-S39
|
artikel
|
| 82 |
PO-66 Patient-reported outcome (PRO) assessment of symptom severity and impairment of daily activities in a group of ambulant cancer patients with IPE: correlation with the Hull score
|
Haque, F.
|
|
|
200 |
S1 |
p. S53
|
artikel
|
| 83 |
PO-96 Pediatric cancer patients receiving therapeutic anticoagulation for VTE have a low bleeding risk, but a high risk of recurrence
|
Lenahan, S.
|
|
|
200 |
S1 |
p. S72
|
artikel
|
| 84 |
PO-89 Performance of the ‘4S rule' to predict short-term outcomes in cancer outpatients with unsuspected pulmonary embolism
|
Font, C.
|
|
|
200 |
S1 |
p. S66-S67
|
artikel
|
| 85 |
PO-65 Pharmaceutical vigilance and education: the first 6 months of a new anticoagulant at a Brazilian cancer institute
|
Rothschild, C.
|
|
|
200 |
S1 |
p. S52
|
artikel
|
| 86 |
PO-25 Plasma levels of activated factor VII–antithrombin complex predict mortality in subjects with liver and colon cancer undergoing curative surgical intervention
|
Martinelli, N.
|
|
|
200 |
S1 |
p. S30-S31
|
artikel
|
| 87 |
PO-29 Plasma levels of procoagulant and anticoagulant factors in patients with acute cancer-associated thrombosis
|
Campello, E.
|
|
|
200 |
S1 |
p. S32
|
artikel
|
| 88 |
PO-113 Platelet function in polycythemia vera and primary myelofibrosis using multiple electrode aggregometry
|
Nytofte, N.S.
|
|
|
200 |
S1 |
p. S81
|
artikel
|
| 89 |
PO-71 Potential for new trial end point: success of functional mammosphere assay in Thrombin Inhibition Preoperatively (TIP) trial in early breast cancer
|
Castle, J.
|
|
|
200 |
S1 |
p. S56
|
artikel
|
| 90 |
PO-81 Predicting symptomatic venous thromboembolic events in hospitalised children with cancer: prospective validation of a risk assessment model
|
Del Borrello, G.
|
|
|
200 |
S1 |
p. S61
|
artikel
|
| 91 |
PO-105 Quantification of citrullinated histones in human blood samples: challenges and development of a nucleosome-based assay to quantify H3Cit-DNA in human plasma
|
Thålin, A.
|
|
|
200 |
S1 |
p. S77
|
artikel
|
| 92 |
PO-79 Red blood cells and hemostasis in cancer
|
Tikhomirova, I.A.
|
|
|
200 |
S1 |
p. S60
|
artikel
|
| 93 |
PO-56 Relationship between clinical presentation of SARS-CoV-2 infection and risk of thromboembolic events and prognosis in cancer patients
|
Catoya Villa, J.L.
|
|
|
200 |
S1 |
p. S45-S47
|
artikel
|
| 94 |
PO-05 Retrospective cohort observational study of venous and arterial thrombotic event rates in POEMS patients: results from the UK-based POEMS registry and mechanistic insights
|
Sayar, Z.
|
|
|
200 |
S1 |
p. S19
|
artikel
|
| 95 |
PO-01 Rivaroxaban (RX) for the prevention of venous thromboembolism (VTE) in cancer patients (CP) receiving chemotherapy (CHT)
|
Sukhanov, V.A.
|
|
|
200 |
S1 |
p. S17
|
artikel
|
| 96 |
PO-51 Saddle pulmonary embolism in the era of incidental events: incidence, clinical findings and outcomes in a single-center cohort
|
Aramberri, M.
|
|
|
200 |
S1 |
p. S43-S44
|
artikel
|
| 97 |
PO-100 Safety of direct oral anticoagulants and vitamin k antagonists in patients with atrial fibrillation and gastrointestinal or urological cancer
|
Ording, A.G.
|
|
|
200 |
S1 |
p. S73-S74
|
artikel
|
| 98 |
PO-67 Short-term outcomes of cancer patients with pulmonary embolism according to the setting (hospital-acquired versus outpatient) at diagnosis in the era of incidental events
|
Aramberri, M.
|
|
|
200 |
S1 |
p. S53-S54
|
artikel
|
| 99 |
PO-12 Statins and risk of cancer in patients with venous thromboembolism: a Danish population-based cohort study
|
Skajaa, N.
|
|
|
200 |
S1 |
p. S24
|
artikel
|
| 100 |
PO-39 Superficial venous thrombosis in patients with active cancer: characteristics and management
|
Ghenassia-Fouillet, L.
|
|
|
200 |
S1 |
p. S37-S38
|
artikel
|
| 101 |
PO-13 Survival after cancer-related venous thrombosis: the Scandinavian Thrombosis and Cancer Study (STAC)
|
Crobach, M.J.T.
|
|
|
200 |
S1 |
p. S24-S25
|
artikel
|
| 102 |
PO-64 Targeting energetic metabolism as therapeutic approach in cancer
|
Moreira-Barbosa, C.
|
|
|
200 |
S1 |
p. S52
|
artikel
|
| 103 |
PO-74 Targeting the procoagulant tumour microenvironment in breast cancer
|
Blower, E.L.
|
|
|
200 |
S1 |
p. S57-S58
|
artikel
|
| 104 |
PO-77 The activity of fibrinogen-like protein 2 (FGL2) is increased in platelets of patients with malignancies
|
Rabizadeh, D.
|
|
|
200 |
S1 |
p. S59
|
artikel
|
| 105 |
PO-02 The CAT score improves targeting of thromboprophylaxis in ambulatory cancer patients in the AVERT study
|
Kumar, V.
|
|
|
200 |
S1 |
p. S17-S18
|
artikel
|
| 106 |
PO-04 The impact of a patient information video on patient awareness and understanding of chemotherapy induced cancer associated thrombosis
|
Baddeley, E.
|
|
|
200 |
S1 |
p. S19
|
artikel
|
| 107 |
PO-98 The occurrence of thrombocytopathy in CLL patients treated with ibrutinib
|
Chasakova, K.
|
|
|
200 |
S1 |
p. S73
|
artikel
|
| 108 |
PO-75 The relationship between the coagulation and inflammatory phases of wound healing in early breast cancer
|
Singh, U.
|
|
|
200 |
S1 |
p. S58
|
artikel
|
| 109 |
PO-48 The risks of chemotherapy induced cancer associated thrombosis: what do patients know and what do they need to know?
|
Baddeley, E.
|
|
|
200 |
S1 |
p. S42
|
artikel
|
| 110 |
PO-50 The role of the blood factors in the survival of patients with non-small cell lung cancer
|
Dimakakos, E.
|
|
|
200 |
S1 |
p. S43
|
artikel
|
| 111 |
PO-76 The T3R domain of thrombospondin-1 delays tumor growth and improves tumor response to chemotherapy by remodeling the tumor vasculature
|
Pinessi, D.
|
|
|
200 |
S1 |
p. S58-S59
|
artikel
|
| 112 |
PO-69 Thrombotic microangiopathy in the differential diagnosis of anemia and thrombocytopenia in patients with pancreatic cancer receiving chemotherapy
|
García de Herreros, M.
|
|
|
200 |
S1 |
p. S54-S55
|
artikel
|
| 113 |
PO-62 Tinzaparin: anti-cancer properties?
|
Dimakakos, E.
|
|
|
200 |
S1 |
p. S51
|
artikel
|
| 114 |
PO-80 Tissue factor and tissue factor in combination with alpha-1 antitrypsin or REG4 associate with venous thromboembolism in patients with colorectal cancer
|
Van Beijnum, R.
|
|
|
200 |
S1 |
p. S60
|
artikel
|
| 115 |
PO-27 Tissue plasminogen activator and risk of breast cancer in a cas–cohort study from Italian women of a general population: results from the Moli-sani study
|
Costanzo, S.
|
|
|
200 |
S1 |
p. S31-S32
|
artikel
|
| 116 |
PO-36 Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomisation of the SELECT-D trial
|
Marshall, A.
|
|
|
200 |
S1 |
p. S36
|
artikel
|
| 117 |
PO-107 Tumor-induced neutrophil extracellular traps contribute to organ failure in individuals with cancer
|
Cedervall, J.
|
|
|
200 |
S1 |
p. S78
|
artikel
|
| 118 |
PO-42 Unprovoked thrombosis: when cancer associated thrombosis could be the first diagnosis – a case report
|
Vilaseca, A.B.
|
|
|
200 |
S1 |
p. S39
|
artikel
|
| 119 |
PO-103 Unravelling the mouse endothelial transcriptome in organs distant from the primary tumor
|
Herre, M.
|
|
|
200 |
S1 |
p. S76
|
artikel
|
| 120 |
PO-88 Validation and comparison of the Protecht, Conko, and Khorana score for prediction of venous thromboembolism in ambulatory cancer patients: a retrospective cohort study
|
Guman, N.A.
|
|
|
200 |
S1 |
p. S65-S66
|
artikel
|
| 121 |
PO-58 Venous and arterial tromboembolic events among hospitalized cancer patients with SARS-COV2 infection
|
Blanco Abad, C.
|
|
|
200 |
S1 |
p. S47-S48
|
artikel
|
| 122 |
PO-61 Venous thromboembolic disease in cancer patients treated with immunotherapy: analysis of the TESEO study
|
Ortega Morán, L.
|
|
|
200 |
S1 |
p. S50
|
artikel
|
| 123 |
PO-18 Venous thromboembolism and risk of cancer in patients with dementia: a Danish population-based cohort study
|
Fuglsang, C.H.
|
|
|
200 |
S1 |
p. S26
|
artikel
|
| 124 |
PO-47 Venous thromboembolism and risk of cancer in patients with diverticular disease: a Danish population-based cohort study
|
Schønfeldt Troelsen, F.
|
|
|
200 |
S1 |
p. S42
|
artikel
|
| 125 |
PO-53 Venous thromboembolism and risk of cancer in patients with psoriasis: a Danish population-based cohort study
|
Sørensen, S.T.
|
|
|
200 |
S1 |
p. S44
|
artikel
|
| 126 |
PO-54 Venous thromboembolism and risk of cancer in users of low-dose aspirin: a Danish population-based cohort study
|
Schønfeldt Troelsen, F.
|
|
|
200 |
S1 |
p. S45
|
artikel
|
| 127 |
PO-14 Venous thromboembolism and risk of cancer in women treated with postmenopausal hormone replacement: a Danish population-based cohort study
|
Svingel, L.S.
|
|
|
200 |
S1 |
p. S25
|
artikel
|
| 128 |
PO-22 Venous thromboembolism in cancer patients – data from Regional Centre for transfusion medicine Shtip
|
Shorova, M.
|
|
|
200 |
S1 |
p. S28-S29
|
artikel
|
| 129 |
PO-11 Venous thromboembolism in ovarian cancer patients: a nationwide Danish cohort study
|
Kahr, H.S.
|
|
|
200 |
S1 |
p. S24
|
artikel
|
| 130 |
PO-60 Venous thromboembolism in patients with advanced non-small cell lung cancer treated with immune check-point inhibitors: a retrospective cohort study
|
Icht, O.
|
|
|
200 |
S1 |
p. S49-S50
|
artikel
|
| 131 |
PO-16 Venous thromboembolism in small cell lung cancer patients: an epidemiological study
|
Dimakakos, E.
|
|
|
200 |
S1 |
p. S25-S26
|
artikel
|
| 132 |
PO-15 Venous thromboembolism may be a marker of occult cancer in patients with kidney disease
|
Kjaergaard, A.D.
|
|
|
200 |
S1 |
p. S25
|
artikel
|
| 133 |
PO-09 Very high-risk patients: a prospective study of thromboembolic events in patients under thromboprophylaxis
|
Liz Pimenta, J.
|
|
|
200 |
S1 |
p. S22
|
artikel
|
| 134 |
Title page
|
|
|
|
200 |
S1 |
p. v
|
artikel
|
Tijdschrift beschrijving